SPECIAL NOTICE
99 -- NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
- Notice Date
- 2/9/2015
- Notice Type
- Special Notice
- NAICS
- 921190
— Other General Government Support
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- S15-054
- Archive Date
- 3/17/2015
- Point of Contact
- SBO Help Desk,
- E-Mail Address
-
sbohelp@mail.nih.gov
(sbohelp@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- National Institutes of Health, National Cancer Institute, Frederick National Laboratory for Cancer Research Opportunities-Special Announcements: This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of solicitation for offers. In accordance with FAR 15.201(d), this special notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to: 1) publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR); and 2) increase participation by qualified HUBZone small business, small, small disadvantaged, women-owned small business, veteran-owned small business and service-disabled veteran-owned small business concerns, as applicable. The FNLCR is a Government-Owned Contractor-Operated (GOCO) Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research Inc. for the National Cancer Institute (NCI) under Prime Contract No. HHSN261200800001E, which provides Operations and Technical Support (OTS) for the Frederick National Lab. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this notice as no information is being requested. Please be advised that any submissions provided despite the aforementioned notice that no information is requested become Government property and will not be returned, nor will there be any ensuing discussions or debriefings of any responses. Responses submitted to this notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. The solicitation referenced below is issued by Leidos Biomedical Research, Inc. (Leidos Biomed), a wholly owned subsidiary of Leidos Corporation under its prime contract with the National Cancer Institute (NCI) at Frederick. Leidos Biomed is the Operations and Technical Support Contractor for the operation of the Frederick National Laboratory for Cancer Research (FNLCR) under contract from the National Cancer Institute (NCI). Leidos Biomed is responsible for managing the scientific and administrative aspects of the FNLCR's research endeavors. Title: Genome Characterization Centers (GCC) Project Background and Objectives: Cancer is a complex and heterogeneous disease in which mutations and other genomic and epigenomic abnormalities play a role in both its initiation and progression. Given cancer's complexity, it is generally believed that only a fraction of alterations that may be useful as characteristic markers of specific tumor types and/or potential molecular targets have been identified to date. In 2006, the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) collaborated to initiate The Cancer Genome Atlas (TCGA) project to determine the feasibility of more comprehensively cataloging the genomic alterations associated with a number of different human cancers. The project demonstrated that cancer-associated genes and genomic regions can be identified by combining diverse information from genome analyses with tumor biology and clinical data, and that the sequencing of selected regions can be conducted efficiently and cost-effectively. The comprehensiveness and rate of progress of TCGA depended on both optimization of technical issues and resource availability. Three key "lessons learned" during the TCGA Program were that, to be able to interpret the results generated by the various characterization platform, the Centers had to a) utilize high quality molecular analytes isolated from well characterized tissue specimens, b) perform experiments utilizing strictly standardized protocols and c) deposit the results in structured and well-described formats. The last lesson strongly impacted on the ability of the various analytical groups to extract meaningful results from the genomic data generated. The overarching goal for the GCCs is the high-resolution, systematic, comprehensive (genome-wide) characterization of cancer-related genomic alterations. These types of characterization should be conducted using validated methods in a high-throughput fashion at the start of the project. The cancer biospecimens for these studies (DNA, RNA, cells [for epigenetic studies of histone modifications] or other types of samples required by a platform) will be provided by the Biospecimen Core Resource of the Center for Cancer Genomics (CCG). The aim is to have all the characterizations conducted on biomolecules from the same biospecimens for optimal analytical integration for data comparability. The GCCs are expected to generate these genomic data by using optimized and standardized high-throughput technologies. Based on this premise, tumor sample eligibility for CCG projects will be based on the analyte quantity and quality requirements of the technologies, which will be centrally verified by the BCR, but may include any histopathological type of tumor. Contact Details: For a copy of the Solicitation please contact: Jessica Staley at Jessica.staley@fnlcr.nih.gov or 301-228-4796 For information concerning other opportunities with the FNLCR, please refer to: http://ncioa.cancer.gov/oa-internet/sbo/welcome.jsp
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/S15-054/listing.html)
- Record
- SN03637258-W 20150211/150209234746-182808a768d6c8ba5a3601e2c7691d49 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |